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A B S T R A C T
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan – a Plan to
improve services to prevent transmission of infection, particularly among people who inject drugs
(PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was
underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding,
will have been invested by 2015), and a web of accountable national and local multi-disciplinary multi-
agency networks responsible for the planning, development and delivery of services. Initiatives ranged
from the introduction of testing in specialist drug services through finger-prick blood sampling by non-
clinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan
was informed by comprehensive national monitoring systems, indicating the extent of the problem not
just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the
number advancing to end-stage liver disease and death, and also through compelling modelling work
demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting.
Achievements include around 50% increase in the proportion of the infected population diagnosed (38%
to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto
therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to
140); and reversing of an upward trend in the overall number of people living with chronic infection. The
Action Plan has demonstrated that a Government-backed, coordinated and invested approach can
transform services and rapidly improve the lives of thousands. Cited as ‘‘an impressive example of a
national strategy’’ by the Global Commission on Drug Policy, the Scottish Plan has also provided
fundamental insights of international relevance into the management of HCV among PWID.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4.0/).prevent the spread of infection, particularly among people who
inject drugs (PWID); (ii) to diagnose HCV-infected people,
particularly those who would most benefit from treatment; and
(iii) to ensure that those infected receive optimal treatment, care
and support (Scottish Executive, 2006). The first phase of the Plan,
involved gathering evidence from a combination of surveillance
and research initiatives to inform proposals for the development of
HCV services (described below); limited additional funding (£2
million per annum) was thus provided during this initial period toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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ment, 2008), launched in May 2008, saw serious commitment from
Scottish Government to deliver actions designed to dramatically
improve prevention, diagnosis and treatment services throughout
the country; by 2015, around £100 million will have been invested
in HCV, additional to that of the general National Health Service
(NHS) budget, in Scotland (a country with a publicly funded
healthcare system). Equating to more than £20 per capita over the
period, the Plan represents one of the most financed and evidenced
national policies on HCV globally. This article provides a review of
the Action Plan in respect of the key evidence which informed
actions, the principles and characteristics underpinning its
implementation, the evidence we now have of the progress made
in diagnosing and treating infection and in preventing severe liver
morbidity (SLM) particularly among PWID, and the challenges and
opportunities which lie ahead.
Key evidence gathered during Phase I of the Action Plan
Fig. 1 provides a summary of the HCV epidemiological
landscape in Scotland during 2006, at the start of the Action Plan.
An estimated 38,000 Scots (0.9% of the adult population) were
living with chronic HCV (i.e. RNA positive); a further 13,000 will
have been infected in the past but have since cleared their HCV
either spontaneously (in the main) or through therapy. Of those
chronically infected, around 90% had acquired their infection
through injecting drug use, the majority (>60%) remained
undiagnosed, less than 10% had attended specialist care and only
1% had been initiated on antiviral therapy during 2006 (Hutch-
inson, Roy, et al., 2006; Hutchinson et al., 2012; McDonald,
Hutchinson, Schnier, McLeod, & Goldberg, 2014; McDonald, Innes,
Hayes, et al., 2014). Serious clinical consequences of chronic HCV
infection were growing rapidly: the annual number newly
hospitalized with HCV-related decompensated cirrhosis (liver
failure) had more than doubled and the associated bed-days more
than tripled between 1996 and 2005 (McDonald, Hutchinson, &
Bird, 2010).
Characterizing the topography of this landscape relied on a
number of monitoring systems, without which the evidence for the
Action Plan could not have been generated, including: a national
HCV diagnosis database, providing data on the numbers diagnosed
(Hutchinson, Roy, et al., 2006; Shaw et al., 2003); a national HCV
clinical database, providing data on the numbers attending
specialist care and being treated (Innes et al., 2012; McDonald,0
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Fig. 1. Estimates of the number of people living with chronic HCV infection (i.e. HCV RNAInnes, Hayes, et al., 2014); and record-linkage of these HCV
databases with other national hospital and deaths registers,
providing data on the numbers advancing to end-stage disease
and death (McDonald et al., 2008, 2009, 2010; Palmateer,
Hutchinson, McLeod, Codere, & Goldberg, 2007).
Modelling work, synthesizing data from these monitoring
systems, further estimated that over 2000 HCV-infected people in
Scotland (involving 1900 people who had ever injected drugs)
were living with cirrhosis in 2005, and the annual number
developing decompensated cirrhosis was projected to double
between 2000 and 2020 unless treatment rates were scaled-up
considerably (Hutchinson, Bird, & Goldberg, 2005). The annual
health service cost of managing chronic disease (excluding HCV
antiviral therapy costs) among people who had ever injected drugs
was estimated to double between 2008 (£9.9 million) and 2030
(£20.2 million), and total £362 million during 2008–2030. Uptake
of antiviral therapy (with pegylated interferon and ribavirin)
needed to increase to 2000 per year, to curb the rising trend in the
prevalence of cirrhosis and incidence of decompensated cirrhosis
(see Figs. 2 and 3). If 2000 persons per year received HCV antiviral
therapy over two decades, an estimated 5200 cases of cirrhosis
and 2700 cases of decompensated cirrhosis could be prevented
in the future.
On the basis of the above evidence, the key actions within the
Phase II Action Plan to address these issues (see Table 1) included
local NHS Boards (of which there are fourteen in Scotland, each
with responsibility for provision of healthcare in their respective
areas) developing services to: improve HCV testing and referral
activities, particularly by GPs and other community setting
practitioners, and increase the numbers of persons undergoing
therapy in Scotland each year in line with Government targets.
Hallmarks of the Action Plan
The Phase II Plan was launched by Scotland’s Health Minister,
who described it ‘‘as an example of best practice in public policy
development’’. It had a number of principles and characteristics
worthy of mention:
(I) Robust evidence base: As described above, the Plan was
developed on the basis of robust evidence, generated through
comprehensive national monitoring systems which quanti-
fied the scale and severity of the problem, and compelling
modeling work which demonstrated the potential beneficial20,00 0 40 ,00 0
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Fig. 2. Modelled incident number of chronic HCV infected people, who had ever
injected drugs, in Scotland developing decompensated cirrhosis (liver failure) each
year according to different uptake rates of HCV antiviral therapy during 2008–2030.
Adapted from Hutchinson et al., 2005.
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acting. Further, HCV antiviral therapy (with pegylated
interferon and ribavirin) had been shown to be highly cost-
effective (NICE, 2006). While this evidence relates to Scotland,
much of it will be cross-transferable to other countries,
particularly those with injecting drug use driven HCV
epidemics.
(II) High-level actions and extensive consultation process: The Phase
II Plan included around 30 actions geared towards developingSevere HCV disease pr evented by HCV anviral therapy*
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Fig. 3. Modelled prevalent number of chronic HCV infected people, who had ever injected
therapy during 2008–2030.
Adapted from Hutchinson et al., 2005.and improving services (Scottish Government, 2008). Dedi-
cated working groups – established during Phase I – were
responsible for reviewing the evidence and translating it into
proposed key issues and actions. These proposals were shared
extensively, including at a consultation event held at the
Royal College of Physicians of Edinburgh where nearly
200 stakeholders provided their approval through a digital
voting system. The actions were high-level in nature, allowing
NHS Boards the freedom to develop services in the context
of existing arrangements and epidemiology of infection in
their area.
(III) Strong governance and clear accountability: The Plan aimed to
put in place mechanisms to ensure better accountability of
services, and to raise awareness of HCV among those who are
responsible for the planning and delivery of services in NHS
boards, local authorities, community health partnerships and
drug and alcohol action teams. The Plan mostly concerned
the development of services by NHS Boards and other
organisations, all of which received funding for this purpose.
Accordingly, these lead organisations were directly account-
able to the Government. To facilitate and ensure this process
was consistent and managed well, a project management
approach was employed in Phase II. A governance board,
comprising representatives from lead organisations, and
advisory board, involving independent experts in the field,
was established to review progress on, and advise on issues
concerning, Action Plan delivery.
(IV) Leadership and co-ordination: Nationally, Health Protection
Scotland (the organisation which coordinates, supports and
advises on health protection activities, including monitoring
of health hazards, across the country) was responsible for
co-ordinating the Action Plan; this involved presiding over
the governance board during Phase II, establishing national
networks to support other lead organisations delivering
different aspects of the Plan, monitoring progress and
performance to help ensure the Plan was delivered in a
timely way, and communicating progress to, and seeking
feedback from, stakeholders. NHS Boards, through their
appointed Hepatitis C Executive Leads (mostly Directors ofdar year Calend ar year
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Table 1
Summary of the key evidence, issues stemming from the evidence, actions designed to address the issues, progress made in delivering actions and associated outcomes, in
respect of testing, treatment, care and support.
Key evidence and issues Key actions Progress and outcomes
Key evidence (mid 2000s)  Each NHS Board will have, or be affiliated
to, a Managed Care Network for HCV; this
Network will comprise representatives of
relevant specialists in healthcare and other
stakeholder groups including those for the
prison service, local authority, social work,
the voluntary sector, mental health/
addictions, and people living with and
affected by HCV
 Testing, treatment, care and support
services within each NHS Board will be
developed to increase the numbers of
persons undergoing therapy in Scotland
from 450/year to 1000 in 2010/11 and at
least, 2000/year thereafter
 Service Level Agreements (SLAs)/
Memoranda of Understanding (MoU)
between NHS Boards and the Scottish
Prison Service, to promote the treatment of
HCV infected inmates in prisons, will be
developed
 Awareness-raising campaigns and
communications initiatives will continue to
be developed, and implemented to meet
the information and education needs of a
range of professional audiences
 An awareness-raising campaign, to
promote HCV testing among those at risk of
being infected, will be implemented
 NHS Boards to develop and implement
innovative approaches to improve HCV
testing and referral activities by GPs and
other community setting practitioners
 A programme of work to evaluate
different approaches to HCV testing/body
fluid sampling (e.g. dried blood spots) will
be undertaken
 All NHS boards have established multi-
disciplinary Managed Care Networks
 A public and professional website was
launched, and public and professional
awareness campaigns undertaken in 2010
 New approaches in getting people tested
for HCV have been implemented; this
includes the roll-out of dried blood spot
(DBS) testing, allowing sampling in non-
clinical settings (i.e. drug treatment
services)
 A 30% increase in the annual number of
persons newly diagnosed with HCV
between periods pre and during the Action
Plan has been observed; around 20% of new
diagnoses in 2011 were made in specialist
drug services where DBS testing has been
introduced
 Around 55% of all persons in Scotland
living with chronic HCV have been
diagnosed (by 2013), a rise from 38% in
2006
 Clinical services – leading to more than a
doubling in the numbers of HCV infected
persons initiated on treatment from 468 in
2007/08 to 1049 in 2010/11 – have been
developed; 80% of initiates in 2010/11 with
a known risk factor had ever injected drugs
 MoU, followed by SLAs, have been agreed
by the majority of NHS Boards and the
prisons within their areas to ensure that
inmates receive optimal care and
treatment; more than a eight-fold increase
in the number of inmates treated between
2007/08 (17) and 2010/11 (143) has been
observed
 National procurement of antiviral drugs
from the two key pharmaceutical
companies, securing, on average, a 20%
reduction in costs, has been implemented
 An estimated 38,000 individuals living with chronic
HCV, of whom around 90% had acquired their
infection through injecting drug use
 Over 60% of people in Scotland living with HCV
infection remained undiagnosed
 Less than 10% of chronically infected individuals had
attended specialist care and only 1% had been initiated
on a course of antiviral therapy, during 2006
 Over 2000 HCV-infected persons were however living
with cirrhosis, and over 100 HCV-infected persons were
developing liver failure each year
 Of 450 persons initiated on antiviral therapy each
year, only 4% were prison inmates
 It was estimated that if 2000 persons per year received
antiviral therapy over the next two decades, 5200 cases
of HCV-related cirrhosis and 2700 liver failures would
be prevented in the future
 Studies undertaken in Glasgow showed that a
targeted approach to HCV testing in the GP setting –
focusing on PWID aged over 30 years – generates a high
test uptake and yield of HCV diagnoses
 GPs and other service providers highlighted
difficulties in taking blood from PWID as a barrier to
HCV test uptake
Major issues
 The majority of persons chronically infected with HCV
remain undiagnosed and many of those diagnosed fail
to reach and stay within specialist care services
 There are widespread variations in testing practice in
the community setting
 Widespread variations in the approach to the clinical
management and social care of HCV-infected persons
exist
 Insufficient numbers of HCV-infected persons,
including prisoners, receive antiviral therapy
 There are insufficient links between social care/
addiction/mental health services and specialist services
for HCV treatment
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ordinating the Plan locally; this involved establishing local/
regional networks to support the planning, development and
implementation of services, and commissioning services.
(V) Multidisciplinary approach: The Plan embraced all service
needs and adopted a multidisciplinary approach. Local and
national networks, comprising representatives from all
relevant healthcare specialists and other stakeholder groups,
were established so that experience, best practice and
progress on the delivery of the Action Plan could be shared,
and support, advice and guidance provided. Thus these
networks ensured that approaches taken were effective and,
where appropriate, consistent.
(VI) Serious investment: The Plan was supported by additional
government funding (£43 million over the initial 3 years); the
bulk (85%) was given to regional NHS boards to develop
testing and treatment (£28.7 million) and prevention (£8
million) services.
(VII) Monitoring and performance measures: Each action within the
Phase II Plan had a desired outcome, performance measure(s)
to gauge progress in achieving the desired outcome, and
timescales. For example, it was anticipated that, by 2011,
actions would lead to considerable increases in the numbers
of persons diagnosed with HCV and the numbers of infected
persons having cleared their virus through antiviral therapy.
Given significant resources were allocated for treatment,
government targets were set to ensure the annual numbers ofpeople undergoing therapy in Scotland increased. To monitor
progress and the impact of actions, the maintenance/
development of existing and establishment of new national
surveillance systems was essential (described below).
Progress and impact
Seven years have elapsed since the launch of Phase II and a
considerable amount of data, permitting evaluation of the plan’s
impact, are now available. Monitoring systems, and use of
advanced statistical analysis/modelling techniques (involving
segmented regression and multi-parameter evidence synthesis),
were vital to understand the scale-up and impact of interventions.
Of particular importance were national HCV diagnosis and clinical
databases to inform on whether measures, to reduce the
proportion of the infected population undiagnosed and increase
the proportion of the infected population treated, were effective
(Innes et al., 2012; McLeod, Weir, et al., 2014; PHE, 2014). During
Phase II, a HCV test database, covering the four largest NHS Board
areas with over 70% of the country’s diagnosed population, was
also established to further understand whether initiatives
designed to increase test uptake and diagnosis were effective.
Biennial nationwide surveys of PWID, principally involving those
actively injecting drugs, were undertaken to gauge the prevalence
and incidence of HCV infection in this population but also uptake of
interventions, such as HCV testing (Palmateer et al., 2014; UWS,
S.J. Hutchinson et al. / International Journal of Drug Policy 26 (2015) 1041–1049 10452015). The annual linkage of the national HCV diagnosis database
to morbidity/mortality records arguably generates the most
important indicator data of all: on the numbers of HCV-infected
people advancing to end stage liver disease and death (McDonald
et al., 2010; PHE, 2014). The following three sections present the
headline data from these systems and associated research
initiatives, and the progress made in diagnosing and treating
infection and in preventing SLM.
Diagnosing infection
From a diagnostic perspective, 2011 saw the highest annual
number of new HCV diagnoses ever made in Scotland, with
around a 30% rise observed in these annual numbers between the
5-year periods pre (averaging 1600) and during/post Phase II
(averaging 2100) (see Fig. 4a) (McLeod, Hutchinson, & Goldberg,
2014). The proportion of people reporting injecting drug use
among those newly diagnosed (and with available risk factor
information) has remained high (90%). Further, estimates
indicate that now around 55% of all persons in Scotland living
with chronic HCV have been diagnosed (by 2013), a rise from 38%
in 2006 (PHE, 2014).
Awareness of HCV among professionals as a consequence of a
wide range of action plan initiatives, including the establishment
of numerous local and national networks, is likely to have played a
role in the promotion of HCV testing. However, the introduction of
dried blood spot (DBS) testing in the specialist drug service setting
in 2009, following laboratory evaluations demonstrating its
validity (Bennett et al., 2012), has had the greatest impact on
the diagnosis effort and has since been deemed cost-effective
(Martin, Hickman, Miners, et al., 2013). This non-invasive
approach, involving finger-prick blood spotted onto filter paper,
enabled staff with minimal training to undertake an HCV test and
thus permitted the roll-out in non-clinical settings (McAllister
et al., 2014). The annual number of people tested for HCV in
specialist drug services across Scotland increased dramatically
from <100 prior to the Action Plan, to over 1000 since, with this
setting now referring almost 20% of all new diagnoses (McLeod,
Hutchinson, et al., 2014; McLeod, Weir, et al., 2014). The
proportion of PWID in Scotland, interviewed at services providing
injection equipment, who had been tested for HCV in the last year
(excluding those already diagnosed) increased from 40% in 2008–
09 to 52% in 2013–14 (PHE, 2014). Accordingly, there is evidence
that a breakthrough has been made in getting infected PWID tested0
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Fig. 4. Annual number of people in Scotland who were (a) newly diagnosed with HCVand diagnosed in Scotland. While HCV testing among PWID is
advocated internationally (WHO, 2014), research conducted in
Scotland underlines the need to act on a diagnosis, as awareness of
one’s infection status was found to be associated with a reduction
in health-related quality of life (McDonald et al., 2013).
Progress has also been observed in the uptake of specialist HCV
services (which remains primarily confined to secondary care)
following HCV diagnosis, with approximately 60% increase in the
total numbers attending between 2006 (3500) and 2013 (5700)
(PHE, 2014). Also, 45% attendance was observed within 12 months
of first diagnosis during Phase II compared to 32% pre-Phase II
(McDonald, Hutchinson, Innes, et al., 2014). However, the
attendance at specialist services (within 12 months of diagnosis)
still varied considerably during Phase II, with lower rates observed
among PWID (39%) compared to non-PWID (63%) and those
diagnosed in drug services (40%) compared to primary care (60%).
These data reflect that further efforts will be required in Scotland
to ensure the vast majority of infected PWID, many of whom are
now being diagnosed within drug treatment services, engage with
HCV treatment and care services. The further co-localization of
HCV management with addiction and other community setting
services, currently confined to a few areas, is a strategy likely to
result in higher treatment rates among PWID (Alavi et al., 2013;
Bruggmann & Litwin, 2013; Zeremski et al., 2013).
Treating infection
From a treatment perspective, much has been achieved in
developing clinical services throughout the country. The founda-
tion of which was the establishment of managed care networks
(MCNs) across Scotland, forming multi-disciplinary multi-agency
networks with responsibility for the planning and delivery of HCV
testing, treatment and care services. Establishing agreements with
the prison service was central to that, to promote the treatment
of HCV-infected inmates. Recognizing that it was not possible
to manage and treat HCV-infected individuals divorced from
concomitant lifestyle issues (drug, alcohol or psychiatric problems
and social care needs), MCNs had to integrate specialist HCV
services with those for social care and mental health/addictions.
Funding from the Action Plan helped to resource specialist nurse
teams enabling an expansion of nurse-led liver assessment and
treatment clinics not just in the main hospital, but in prison and, in
some areas, community settings such as drug treatment services
(Tait, McIntyre, McLeod, Nathwani, & Dillon, 2010).200
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up in interventions (solid line), and (b) not taking account of the impact of the
national scale-up in interventions (dashed line).
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antiviral therapy had more than doubled (and increased more than
eightfold among prisoners) from 468 (and 17) in 2007/08 to 1049
(and 143) in 2010/11, which exceeded Scottish Government
targets during this period (PHE, 2014) (see Fig. 4b). Since then, the
annual treatment numbers have remained close to 1000, which fall
slightly short of Government targets but likely reflect a delay in
treatment initiation for many individuals due to the prospect of
more effective therapies in the near future. Of critical importance is
the observation that, for the great majority of this group, injecting
drug use was the principal risk factor for HCV transmission. Among
people initiated on therapy across Scotland (and with available risk
factor information), the proportion who had reported having ever
injected drugs increased from 65% (300) in 2007/08 to 80% (840) in
2010/11, corresponding to around a tripling in treatment uptake in
this population. Despite the country-wide scale-up in therapy –
and inevitable expansion into increasingly more difficult and0
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Fig. 6. Annual number of people in Scotland diagnosed HCV antibody positive and wh
hepatocellular carcinoma.complex groups of patients – there was no evidence that SVR rates
had been compromised in Scotland (McDonald, Hutchinson, Innes,
et al., 2014). It is therefore evident that having a history of injecting
drug use, per se, is no barrier to receiving, and indeed fully
benefitting from, combination therapy.
An important turning point was reached during the Action Plan
period, whereby the number of people living with chronic HCV
infection in Scotland started to decline – an observation which
contrasts sharply with the increasing trend estimated for the years
leading up to Phase II (see Fig. 5). This decline stems essentially
from (a) an increase in the annual number of people clearing their
chronic infection from therapy, and (b) a decrease in the estimated
annual number of PWID becoming newly infected. Approximately
37,000 people were estimated to be chronically infected during
2013, which is lower than the 38,000–39,000 estimated during
2006–2008, in the early phase of the Action Plan (PHE, 2014).
Further, the estimated total of 37,000 by 2013 is considerably
lower than a projected total of almost 42,000, assuming a
continuing upward trend in the size of the chronic HCV population
– and thus no change in the numbers of people clearing HCV from
therapy or those newly acquiring infection – as estimated during
2006–2008 (see Fig. 5).
Preventing severe liver morbidity
The ultimate aim of the Action Plan was to reduce the numbers
of infected persons who develop severe HCV-related disease.
The annual numbers of persons diagnosed HCV-antibody positive
who had been hospitalized for the first time with SLM (defined
as either decompensated cirrhosis or hepatocellular carcinoma)
had more than doubled in the decade leading up to the Action
Plan, from approximately 40 in 1996 to 100 in 2005 (see Fig. 6).
These numbers continued to increase, plateaued at approximately
150 cases per annum during 2009–2012, and increased again to
near 190 cases in 2013. This continuing upward trend is consistent
with the statistical modelling work (Hutchinson et al., 2005),
which informed the Plan and highlighted that greater treatment
rates (double that which has been achieved) would be required
to curb the rise in SLM (see Fig. 2). All-cause and liver-related00 4 200 5 200 6 200 7 20 08 200 9 20 10 201 1 201 2 201 3
Never Injected Not Known
o had been hospitalised for the first time with either decompensated cirrhosis or
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among the HCV diagnosed population in Scotland during 2005–
2010, a further indicator that therapy has so far had minimal
impact on population level HCV-related disease (Aspinall et al.,
2015). At an individual level, however, Scotland has been at the
forefront internationally in demonstrating that attainment of SVR
following therapy is significantly associated with a reduced risk of
a broad range of outcomes: including hepatic, non-hepatic and
those driven by extreme lifestyle behaviours (Innes et al., 2015).
So, while Scotland has managed to scale-up diagnosis and
treatment, the continuing rise in SLM since Phase II of the Action
Plan likely reflects that (i) treatment uptake – although ranking
high internationally (Dore, Ward, & Thursz, 2014) – is still
relatively low at around 3% per annum, (ii) SVR rates – although
in keeping with what you would expect during an era dominated
by pegylated interferon and ribavirin – have nevertheless been
suboptimal (ranging from 39% with genotype 1 to 70% with
genotype 2/3) (Innes et al., 2012), (iii) insufficient numbers of
infected persons with significant fibrosis (METAVIR score F3–F4) –
representing those most in need of therapy from a clinical
perspective – being initiated on therapy (relating to only around
300 of the 1000 annual treatment initiates in Scotland), and (iv) the
extent of excessive alcohol intake in those with HCV infection in
Scotland, and limited impact of measures aimed at tackling it (an
estimated 36% of all cases of cirrhosis among persons attending
specialist HCV services would not have occurred if such individuals
had not drank to excess (Innes et al., 2013)). Among those developing
SLM in 2013, 92% of those (with available risk factor information)
had reported injecting drug use (Fig. 6) and 53% were aged at least
50 years of age. These data highlight that not enough has been done
to tackle HCV among those individuals who acquired their infection
during the rapid rise of heroin use in Scotland in the late 1970s and
early 1980s (Hutchinson, Bird, Taylor, & Goldberg, 2006); thus, as
a consequence, we are now experiencing the subsequent wave of
PWID-related late HCV sequelae.
Challenges and opportunities which lie ahead
The future holds much promise with the advent of highly
effective therapies, eradicating the virus in the vast majority of
patients. This watershed in HCV treatment however comes at a
price; for Scotland, it theoretically translates to a bill of the order of
£1 billion in antiviral drug costs alone (assuming an average cost of
£25,000 per course of therapy), almost a tenth of the entire annual
health budget, to treat all infected individuals across the country.
Clearly the prohibitive cost of the new regimens represents a
significant challenge, not just for Scotland but, for all countries
affected by HCV. The following sections present the latest evidence
on the challenges and opportunities facing Scotland in its bid to
fully achieve the three aims of the action plan.
Treatment to prevent onward transmission among PWID
Considerable progress has been made in scaling up the
provision of harm reduction interventions (i.e. injecting equipment
provision (IEP) and opiate substitute therapy (OST)) in Scotland,
known to appreciably reduce the risk of HCV infection if given at
sufficient levels and in combination (Palmateer et al., 2014; Turner,
Hutchinson, & Vickerman, 2011). Whilst there is evidence to
suggest a reduction in the incidence of HCV infection has taken
place among PWID in Scotland (from 13.3 per 100 person years
during 2008–09, to 6.1 and 10.0 per 100 person years during 2011–
12 and 2013–14, respectively), the prevalence of HCV still remains
relatively high (at least 20%) among individuals who have
commenced injecting in the last 3 years (Palmateer et al., 2014;
PHE, 2014). Mathematical modelling work has suggested thatsubstantial reductions in the prevalence of chronic HCV among
PWID populations cannot be achieved with IEP and OST alone and
would require the scaling up of HCV antiviral therapy, an approach
which has the potential to not only eradicate the virus for the
individual but also prevent the onward transmission to others
(Martin, Hickman, Hutchinson, Goldberg, & Vickerman, 2013).
A meta-analysis demonstrated that acceptable treatment
outcomes can be achieved in patients who report actively injecting
drugs and who are eligible and committed to starting HCV therapy
(Aspinall et al., 2013). Treatment uptake specifically among those
actively injecting drugs in Scotland is estimated to have doubled
during the Action Plan period; the numbers still constitute a
minority (10–15%) of those initiated on treatment each year (Innes,
Goldberg, Dillon, Hutchinson, 2014). With the introduction of
interferon-free therapies (achieving typically 90% SVR), the
annual incidence of chronic HCV is estimated to reduce to
approximately 500, 300, and <50 new infections by 2025 with
treatment of around 100, 300 and 600 PWID per year in Scotland,
respectively (Innes, Goldberg, Dillon, et al., 2014). While these
projections are consistent with previous research (Martin, Vicker-
man, Grebely, et al., 2013), they, nevertheless, are generated from
modeling studies; accordingly, further observational or experi-
mental studies are needed to evaluate whether treatment can
indeed prevent onward transmission, and ultimately control the
spread of HCV, in PWID populations.
Diagnosing the undiagnosed
With an estimated 55% of the infected population diagnosed,
Scotland ranks among the highest internationally; however, a few
countries, notably Australia and Sweden, report rates in excess of
80% (Dore et al., 2014). It could take another decade to achieve
these high rates based on the current pace of testing/diagnosis, in
Scotland. While DBS testing in drug treatment settings is effective
in diagnosing PWID, its reach is limited to those still in contact
with services and generally younger in age (45% aged <35 years)
(McAllister et al., 2014). Recent modelling work has estimated that
27,000 people who had ever injected drugs remained undiagnosed
(in 2009) and, of these, 71% were aged 35 years and 83% had not
injected recently (Prevost et al., 2015). Thus, additional case-
finding will be needed to identify this older population of PWID,
many of whom will no longer be in contact with drug services.
Birth cohort screening has been recommended in the United States
on the back of an economic evaluation (Rein et al., 2012), but such
an approach is not guaranteed to be cost-effective in Scotland
unless perhaps targeted at areas of high HCV prevalence.
Evaluations of case-finding approaches in Glasgow have
demonstrated that targeting older individuals (aged 30–54 years)
with a history of injecting drug use, as indicated within primary
care administrative systems, can be highly effective (Anderson
et al., 2009; Cullen et al., 2012). However, the limited implemen-
tation of this systematic risk-based approach across Scotland to
date likely reflects the difficulty in getting GPs fully engaged in
such case-finding initiatives. It remains uncertain as to whether
incentives, as adopted in the aforementioned evaluations and with
so many other conditions, would appreciably increase HCV testing
and diagnosis by GPs. With the potential to treat people with short,
safe and easy to administer HCV therapies, case-finding and
treatment in the primary care setting could however become more
widely embraced.
Treatment to prevent severe liver morbidity
In an era of highly effective interferon-free therapies, the
numbers of HCV-infected people developing SLM should be
avoidable in the great majority of instances. Modelling work has
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reduce the incidence of HCV-related SLM in Scotland over the next
5 years but it will require increased uptake of therapy, particularly
among those with moderate to advanced fibrosis (Innes, Goldberg,
Dillon, et al., 2014). During 2009–2013, approximately 60% of
treatment initiates in Scotland had mild fibrosis (Innes, Goldberg,
Dillon, et al., 2014), reflecting the wider population being
diagnosed and entering specialist services but also a group
unlikely to progress to SLM in the short term (Huang et al.,
2015; Innes, Goldberg, Dusheiko, 2014). The current high cost of
regimens will likely mean that healthcare providers will now have
to focus treatment, at least initially, on those with more significant
fibrosis (EASL, 2014). The population impact of therapy will
however not be fully realized unless heavy alcohol use and other
harmful lifestyle factors, highly prevalent among HCV-infected
PWID populations, are tackled (Innes et al., 2011).
Conclusion
Scotland’s Hepatitis C Action Plan has been cited as ‘‘an
impressive example of a national strategy’’ by the Global
Commission on Drug Policy (GCDP, 2013). The Plan has shown
that a Government-backed, coordinated and invested approach
can transform services for PWID and rapidly improve the lives of
thousands. The surveillance and research initiatives described
here, provided the clinical and public health champions with the
necessary ammunition to raise awareness and convince policy-
makers of the imperative need for action on HCV, a condition
which disproportionately affects those living in the most deprived
parts of the country. This exceptional affinity with deprivation
(with over half of the HCV diagnosed population residing in the
20% most deprived areas) was no doubt a key factor in securing
Scottish Government’s commitment, given its flagship mission to
tackle health inequalities. The support of governments in other
countries could similarly be garnered through aligning action on
HCV with political agendas and aspirations.
It is evident that a considerable amount of progress has been
made in expanding access to HCV treatment among PWID across
Scotland, particularly among those in prison and in contact with
drug treatment services. The evaluation of the Plan’s impact,
disseminated extensively through national/international confer-
ences and peer-review publications, has further provided funda-
mental insights to the international audience on the management
of HCV among PWID. Serious challenges remain, with tens of
thousands – an appreciable and growing proportion with
significant fibrosis – still requiring therapy and almost half
remaining undiagnosed. Going forward, Scottish Government
has further endorsed its commitment to tackle HCV, with new
targets, informed by the latest modelling work (Innes, Goldberg,
Dillon, et al., 2014), set to reduce the number of people developing
HCV-related SLM to 50 by 2020 (a near 75% reduction within
5 years) and an associated uplift in funding. Scotland’s strategy on
HCV will continue to be closely monitored – as should be the case
for other countries – and judged ultimately according to its ability
to prevent HCV-related SLM.
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